
Alpha Profiles · Company Profile
Nautilus Biotechnology, Inc.
Canonical company identity and public leadership record.
https://registry.alpha.ac/companies/nautilus-biotechnology-inc
- Entity
- Public listing published
- Primary listing
- NASDAQ: NAUT
- Verification
- Partially verified
- Last reviewed
- 2026-10-17T04:46:35.948617+00:00
Overview
Alpha's canonical identity and public leadership record for Nautilus Biotechnology, Inc..
Canonical AEGIS identity graph
Executive leadership
Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.
Executive team
6 public recordsChief Financial Officer and Treasurer
- State
- confirmed
- Effective
- From Apr 28, 2026
- Confidence
- 94%
- Evidence
- NAUT DEF 14A executive officersApr 28, 2026
- State
- confirmed
- Effective
- From Apr 28, 2026
- Confidence
- 94%
- Evidence
- NAUT DEF 14A executive officersApr 28, 2026
Chief Marketing Officer
- State
- confirmed
- Effective
- From Apr 28, 2026
- Confidence
- 94%
- Evidence
- NAUT DEF 14A executive officersApr 28, 2026

General Counsel
- State
- confirmed
- Effective
- From Apr 28, 2026
- Confidence
- 94%
- Evidence
- NAUT DEF 14A executive officersApr 28, 2026
Senior Vice President, Product Development
- State
- confirmed
- Effective
- From Apr 28, 2026
- Confidence
- 94%
- Evidence
- NAUT DEF 14A executive officersApr 28, 2026
Chief Executive Officer, President, Secretary and Director
- State
- confirmed
- Effective
- From Apr 28, 2026
- Confidence
- 94%
- Evidence
- NAUT DEF 14A executive officersApr 28, 2026
Governance leadership
Boards & Committees
Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.
Record as of Oct 17, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.
Board roles
8 public records- State
- confirmed
- Effective
- From Jan 1, 2021
- Confidence
- 85%
- Evidence
- Nautilus Biotechnology, Inc. DEF 14A 2025-04-29Apr 29, 2025
- State
- confirmed
- Effective
- From Jan 1, 2022
- Confidence
- 85%
- Evidence
- Nautilus Biotechnology, Inc. DEF 14A 2025-04-29Apr 29, 2025
- State
- confirmed
- Effective
- From Jan 1, 2021
- Confidence
- 85%
- Evidence
- Nautilus Biotechnology, Inc. DEF 14A 2025-04-29Apr 29, 2025
- State
- confirmed
- Effective
- From Jan 1, 2021
- Confidence
- 85%
- Evidence
- Nautilus Biotechnology, Inc. DEF 14A 2025-04-29Apr 29, 2025
- State
- confirmed
- Effective
- From Jan 1, 2021
- Confidence
- 85%
- Evidence
- Nautilus Biotechnology, Inc. DEF 14A 2025-04-29Apr 29, 2025
- State
- confirmed
- Effective
- From Jan 1, 2021
- Confidence
- 85%
- Evidence
- Nautilus Biotechnology, Inc. DEF 14A 2025-04-29Apr 29, 2025
- State
- confirmed
- Effective
- From Jan 1, 2021
- Confidence
- 85%
- Evidence
- Nautilus Biotechnology, Inc. DEF 14A 2025-04-29Apr 29, 2025
- State
- confirmed
- Effective
- From Jan 1, 2021
- Confidence
- 85%
- Evidence
- Nautilus Biotechnology, Inc. DEF 14A 2025-04-29Apr 29, 2025
Committees
3 public recordsMembership and chair roles are projected from current board seats. A chair is shown only when a stored chair flag says so.
Audit
- Chair
- Melissa Epperly
- Members
- Melissa Epperly (Chair); Matthew L. Posard; Matthew McIlwain
Compensation
- Chair
- Matthew L. Posard
- Members
- Matthew L. Posard (Chair); Farzad Nazem; Karen Akinsanya; Michael Altman
Nominating and Governance
- Chair
- Matthew McIlwain
- Members
- Matthew McIlwain (Chair); Melissa Epperly; Vijay Pande
Source record
Alpha canonical company public projection
Supports Company identity, Published leadership, Entity status boundary
Reviewed 2026-10-17T04:46:35.948617+00:00


